IMMX
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in Nexicart-2 U.S. Trial of Sterically-Optimized CAR-T Nxc-201 in Relapsed/Refractory Light Chain (Al) Amyloidosis
时间：2024-12-19 22:35:00 市场： 美股 综合
Immix Biopharma Advances CAR-T Nxc-201 to Expansion Cohort Dose Level in U.S. Al Amyloidosis Trial Nexicart-2
时间：2024-10-02 21:32:04 市场： 美股 综合
Immix Biopharma Announces DR. Raymond Comenzo, Internationally Recognized Al Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
时间：2024-09-19 21:31:00 市场： 综合 美股